Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

(2018) Robert P. Hirten et al.   Clinical Gastroenterology and Hepatology

Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review for Development of a Core Outcome Set

(2018) Christopher Ma et al.   Clinical Gastroenterology and Hepatology

882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study

(2018) William J. Sandborn et al.   GASTROENTEROLOGY

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease

(2018) Heike Schmitt et al.   GUT

OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)

(2018) S Danese et al.   Journal of Crohns & Colitis

Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn's Disease

(2017) Brian G. Feagan et al.   GASTROENTEROLOGY

Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases

(2017) Clara Abraham et al.   GASTROENTEROLOGY

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

(2017) Parakkal Deepak et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

(2017) Siew C Ng et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Innate Lymphoid Cells in Intestinal Inflammation

(2017) Alessandra Geremia et al.   Frontiers in Immunology

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

(2016) Yanli Zhuang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease

(2016) Vipul Jairath et al.   Journal of Crohns & Colitis

What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance

(2016) Ailsa L. Hart et al.   Journal of Crohns & Colitis

Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells

(2016) David R Withers et al.   NATURE MEDICINE

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation

(2016) Claire Pearson et al.   eLife

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD

(2015) Egle Kvedaraite et al.   GUT

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

(2015) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

(2015) Reena Khanna et al.   LANCET

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

(2015) Sanjaya Singh et al.   mAbs

Clinical improvement in psoriasis with specific targeting of interleukin-23

(2015) Tamara Kopp et al.   NATURE

Immunopathogenesis of IBD: current state of the art

(2015) Heitor S. P. de Souza et al.   Nature Reviews Gastroenterology & Hepatology

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical development of AMG 139, a human antibody specifically targeting IL-23

(2014) K Köck et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interleukin 23 in Crohnʼs Disease

(2014) Ahmet Eken et al.   INFLAMMATORY BOWEL DISEASES

IBD and health-related quality of life — Discovering the true impact

(2014) Sanna Lönnfors et al.   Journal of Crohns & Colitis

Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12- and IL-15-Responsive IFN-γ-Producing Cells

(2013) Anja Fuchs et al.   IMMUNITY

Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications

(2012) Jun R. Huh et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid Cells

(2011) Ju Qiu et al.   IMMUNITY

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity

(2011) Z. Liu et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice

(2011) J H Cox et al.   Mucosal Immunology

Differentiation of Effector CD4 T Cell Populations

(2010) Jinfang Zhu et al.   Annual Review of Immunology

Development of the Crohnʼs disease digestive damage score, the Lémann score

(2010) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology

(2010) Sofia Buonocore et al.   NATURE

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

A protective function for interleukin 17A in T cell–mediated intestinal inflammation

(2009) William O'Connor Jr et al.   NATURE IMMUNOLOGY

IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12

(2008) D. van de Wetering et al.   INTERNATIONAL IMMUNOLOGY